1. Academic Validation
  2. Fragment-based discovery of small molecule inhibitors of the HDGFRP2 PWWP domain

Fragment-based discovery of small molecule inhibitors of the HDGFRP2 PWWP domain

  • FEBS Lett. 2024 Jul 19. doi: 10.1002/1873-3468.14981.
Xiaoli Wei 1 Shuju Li 1 Zihuan Li 1 Lei Wang 1 Weiwei Fan 1 Ke Ruan 1 Jia Gao 1
Affiliations

Affiliation

  • 1 Department of Medical Oncology, The First Affiliated Hospital & School of Life Sciences, Ministry of Education Key Laboratory for Membrane-less Organelles & Cellular Dynamics, Hefei National Research Center for Interdisciplinary Sciences at the Microscale, Biomedical Sciences and Health Laboratory of Anhui Province, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Abstract

The PWWP domain of hepatoma-derived growth factor-related protein 2 (HDGFRP2) recognizes methylated histones to initiate the recruitment of homologous recombination repair proteins to damaged silent genes. The combined depletion of HDGFRP2 and its paralog PSIP1 effectively impedes the onset and progression of diffuse intrinsic pontine glioma (DIPG). Here, we discovered varenicline and 4-(4-bromo-1H-pyrazol-3-yl) pyridine (BPP) as inhibitors of the HDGFRP2 PWWP domain through a fragment-based screening method. The complex crystal structures reveal that both Varenicline and BPP engage with the aromatic cage of the HDGFRP2 PWWP domain, albeit via unique binding mechanisms. Notably, BPP represents the first single-digit micromolar inhibitor of the HDGFRP2 PWWP domain with a high ligand efficiency. As a dual inhibitor targeting both HDGFRP2 and PSIP1 PWWP domains, BPP offers an exceptional foundation for further optimization into a chemical tool to dissect the synergetic function of HDGFRP2 and PSIP1 in DIPG pathogenesis.

Keywords

PWWP domain; fragment‐based screening; hepatoma‐derived growth factor‐related protein 2; histone methylation readers.

Figures
Products